TMB, TIL frequency, MMR deficiency and predicted neoantigen load all correlate with clinical responses to checkpoint blockade by both a-CTLA4 and a-PD-1 across a range of cancers [30,46,51,64,67,68,69,70,71,72,162,163]. This evidence concerns the gene PDCD1 and cancer.